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Objective: To characterize antithrombin (AT) levels in normal pregnancy.
Methods:We performed secondary analyses with data from 3 studies. Using a single measurement from each
subject in the ﬁrst analysis (cross-sectional), we correlated AT levels with gestational age from the middle of
the second trimester throughout the third trimester of pregnancy. Using serial measurements in a second
analysis (cohort), we compared AT levels between the late ﬁrst and second trimesters of pregnancy and baseline
(the level at 6 weeks postpartum). Using serial measurements in a third analysis (cohort), we analyzed the pat-
tern of change in AT levels in the immediate postpartum period. Assays of AT activity were performed using the
Dade Behring (Siemens) Berichrom Antithrombin III Chromogenic Assay. AT levels were correlated with gesta-
tional age using the Pearson correlation coefﬁcient and compared between the different time points using
one-way ANOVA.
Results: Overall, AT levels were 20% lower than baseline during pregnancy (p b 0.01). There was no signiﬁcant
difference between AT levels obtained between late ﬁrst trimester and late second trimester. Frommidtrimester
to term, however, AT levelswere negatively correlatedwith gestational agewith a 13% drop during this period of
time (r = −0.26 [−0.39,−0.11]; p b 0.01). Immediately after childbirth, AT levels fell precipitously to 30%
below baseline (p b 0.05) and reached a nadir 12 hours postpartum before rising and returning to baseline by
72 hours postpartum.
Conclusion: It appears that antithrombin (AT) is consumed at the time of delivery. Our ﬁndings have implications
for AT replacement or even anticoagulation at the time of delivery.© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Antithrombin (AT) is a natural anticoagulant which plays a poten-
tially important role in whether women develop thromboembolism
during pregnancy. Multiple reports have documented an association
between inherited deﬁciency of AT and an increased rate of venous
thromboembolism (VTE) [1]. In pregnancy, the rate of VTE is corre-
spondingly higher. Historic series have reported rates as high as 18 to
70% [2–4]. Differences in these rates may be attributed to the relatively
small numbers in each series, to selection bias and to the varied deﬁni-
tions of AT deﬁciency between series. A well-conducted study enrolled
AT deﬁcient female family members of AT deﬁcient patients with a
history of VTE. The subjects had no history of VTE prior to pregnancy.
The incidence of pregnancy-related VTE among the subjects was 1/33
pregnancies or 3% [5]. This rate is not nearly as high as the historic series,
but considerably higher than the background rate of pregnancy-relatedthe Department of Obstetrics &
s & Gynecology, DUMC 3967,
19 681 7861.
. This is an open access article underthrombosis which is 0.1 to 0.2% [6]. A systematic review includingmore
recent studies (some with more liberal thresholds and not all requiring
a positive family history) found a lower risk of VTE in pregnancy than
the initial studies, but still found an odds ratio 4.76 [95% conﬁdence
interval 2.15, 10.57]). Recently, even mild AT deﬁciency has been
found to be associated with an increased risk for VTE [7,8].
AT is the substrate for heparin, the preferred class of anticoagulant
for the prevention and treatment of thrombosis in pregnancy [9].
Because women have a four- to ﬁve-fold increased risk of thromboem-
bolism during pregnancy [10,11], women are not infrequently
prescribed a heparin during pregnancy and and/or the postpartumperi-
od because of current thrombosis or because of a history of thrombosis.
In the absence of heparin, AT has low inhibitory activity against throm-
bin. However, when heparin is bound to its binding site on AT, inhibito-
ry activity is increased at least 1000-fold. [12] AT inactivates thrombin
by binding to the active serine of thrombin and to the active serine of
activated factor X (FXa) [1]. AT has the ability to inactivate other coagu-
lation factors, including factors IXa, XIa, and XIIa [1]. Importantly, in the
absence of AT, heparin has little to no effect.
AT concentrates have been available since 1979 [13] and are indicat-
ed for the treatment of women with AT during pregnancy or thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Characteristics of the Subjects.
Secondary
Analysis
1 (n = 172)
Secondary
Analysis
2 (n = 120)
Secondary
Analysis
3 (n = 13)
Mean Age
(95% conﬁdence interval)
33.9 (33.4, 34.3) 29.7 (28.6, 30.7) 31.9 (29.1, 35.4)
Race/ethnicity
white 78 (45%) 47 (39%) 9 (69%)
African American 82 (48%) 54 (45%) 3 (23%)
Hispanic 7 (4%) 9 (8%) -
Asian 4 (2%) 10 (8%) 1 (8%)
Unknown 1 (1%) - -
Parity
0 37 (22%) 63 (53%) 3 (23%)
≥ 1 135 (78%) 57 (47%) 10 (15%)
Mode of delivery
vaginal 73 (61%) 10 (77%)
cesarean 40 (33%) 3 (23%)
second trimester loss 3 (3%) -
unknown 4 (3%) -
649A.H. James et al. / Thrombosis Research 134 (2014) 648–651postpartum period when anticoagulation is inadequate to prevent or
treat thrombosis in womenwith AT deﬁciency or when anticoagulation
is desired, but contraindicated [14]. AT concentrates have also been
used in an attempt to prolong pregnancy in severe preeclampsia [15].
There are not only limited data about AT levels in patients with AT deﬁ-
ciency or severe preeclampsia during pregnancy, there are limited data
about AT levels in normal pregnancy. Some investigators have found
decreased AT levels in the third trimester of pregnancy or immediately
postpartum and others have found no change [16–22]. The purpose of
this study was to characterize AT levels in normal pregnancy.
Methods
We performed secondary analyses with data from three different
studies to characterizeAT levels. As the studies had other primary objec-
tives, no sample size calculationsweremade for these secondary analy-
ses. The studies from which the subjects were derived and the overall
study of AT levels were approved by the Duke Institutional Review
Board. Using a single measurement from each subject in the ﬁrst analy-
sis (cross-sectional), we correlated AT levels with gestational age from
the middle of the second trimester throughout the third trimester of
pregnancy. Using serial measurements from the same subjects in a
second analysis (cohort), we compared AT levels between the late
ﬁrst trimester of pregnancy, the late second trimester of pregnancy
and baseline (the level at 6 weeks postpartum). Again, using serialmea-
surements from the same subjects in a third analysis (cohort), we
analyzed the pattern of change in AT levels in the immediate postpar-
tum period. AT levels were compared between the different time points
using one-way ANOVA (JMP statistics software [SAS] v. 10.0.2).
Subjects in the ﬁrst analysis (cross-sectional) comprised 172 preg-
nant women who were each sampled a single time from midtrimester
throughout the third trimester of pregnancy. The study population
was derived from normal control subjects who were enrolled at
Duke University Medical Center as part of a multi-center study of
thrombophilia and intrauterine growth restriction (IUGR) during the
time period of August 2003 to December 2006. Mothers age 18 or
olderwith normally-grown singleton gestationswere enrolled between
25 and 40 weeks. Subjectswith documented congenital or chromosom-
al anomalies, preeclampsia or prolonged premature rupture of the
membranes (N4 weeks) were excluded. Subjects with a history of
deep vein thrombosis or other thromboembolic event, or who were
receiving anticoagulation therapy in the form of low molecular-
weight-heparin (LMWH) or unfractionated heparin (UFH), were also
excluded. A sample of approximately 25 cc of bloodwas collected by ve-
nipuncture in standard 4.5 mL 3.2% sodium citrate tubes from each
subject. Within 4 hours of the blood draw, specimens were processed
and plasma separated. Assays of AT activity were performed in real
time using the Dade Behring (Siemens) Berichrom Antithrombin III
Chromogenic Assay at the Duke Coagulation Laboratory. The normal
range for AT levels at the time of the three studies was 73 to 132 IU/dL
with a coefﬁcient of variation of b 10% (2 to 8%). Demographic data in-
cluding maternal age, race, gestational age, height, weight, medical
comorbidities, and personal habits (i.e. tobacco use) were obtained at en-
rollment. A total of 182 potential subjects were identiﬁed. Ten were
excluded after enrollment – 9 due to insufﬁcient sample and one due to
development of preeclampsia. AT levels were correlated with gestational
age using the Pearson correlation coefﬁcient (GraphPad Prism software).
Subjects in the second analysis (cohort) comprised 120 pregnant
women who were participating in a study of hemostatic variables in
pregnancy, were 18 years of age or older, were planning to deliver at
DukeUniversityMedical Center, were in theirﬁrst trimester of pregnan-
cy, were less than 14 weeks gestation and had documented fetal viabil-
ity. Subjects who had multiple gestation, had a known bleeding
disorder, were on anticoagulation or were on an antiplatelet agent
were excluded. Samples were collected by venipuncture during the
late ﬁrst trimester (12-14weeks gestation), in the late second trimester(between 24 and 28 weeks gestation), and at 6 weeks postpartum
(baseline). Samples were obtained and processed the same as for the
subjects in the ﬁrst analysis except that after processing samples were
frozen and stored at−80° c. Assays were performed on batched sam-
ples, which had not been previously thawed, and were performed
otherwise the same as for the subjects in the ﬁrst analysis. AT levels
were compared between the different time points using one-way
ANOVA (JMP statistics software [SAS]).
Subjects in the third analysis (cohort) comprised 13 normal women
without von Willebrand disease who were participating in a study of
von Willebrand factor levels in pregnancy. Subjects were enrolled
during the last trimester of pregnancy from obstetric clinics at Duke
University. For each subject, an AT level was analyzed from the samples
obtained at enrollment, on admission to the hospital for childbirth, and
at 4 hours, 12 hours, 1 day, 2 days, 3 days, 7 days, 14 days, 21 days,
28 days, and 42 days postpartum. Samples were obtained, stored, proc-
essed and analyzed the same as for the subjects in the second analysis.
AT levels were compared between the different time points using one-
way ANOVA (JMP statistics software [SAS]).
Results
Secondary Analysis 1
The subjects comprised 172 pregnant women who were each sam-
pled a single time between 25 and 40 weeks gestation. For the age,
racial/ethnic distribution and parity see Table 1. Because there are
data that suggest that African Americans have lower antithrombin
levels [23], the racial/ethnic distribution was examined over the range
of gestational ages studied and was found to be constant. Speciﬁcally,
African Americans accounted for 49% of the subjects b 34 weeks gesta-
tion and 46% of the subjects ≥ 34 weeks gestation. Therefore, a greater
proportion of African Americans later in pregnancy could not account
for any observed decrease in AT levels with advancing gestational age.
AT levels were negatively correlated with gestational age (r =−0.26
[−0.39, −0.11]; p b 0.01). As gestational age increased, AT levels
decreased. See Fig. 1. There was a 13% drop from a predicted mean of
105 IU/dL at 25 weeks to 91 IU/dL at 40 weeks gestation.
Secondary Analysis 2
The subjects comprised 120 pregnant women. For the age, racial/
ethnic distribution, parity and modes of delivery see Table 1. Serial AT
levelswere obtained in the late ﬁrst trimester, in the late second trimes-
ter and at 6 weeks postpartum (the baseline level). By 12–14 weeks
Fig. 1. Antithrombin levels by gestational age from 25 to 40 weeks in a cross-sectional
sample of 172 women.
Fig. 3. Serial antithrombin levels from a single cohort (n= 13) sampled frequently during
the postpartum period.
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75, 83). At 24–28 weeks themeanAT levelwas 82 IU/dL (95% CI 78, 87).
As expected, by 6 weeks postpartum, the mean AT level was back to
baseline at 100 IU/dL (95% CI 96, 105). The pregnancy levels, although
not signiﬁcantly different from each other, were both signiﬁcantly
lower than baseline levels by approximately 20% (p b 0.01). See Fig. 2.
Secondary Analysis 3
The subjects comprised 13 normal women. For the racial/ethnic dis-
tribution, parity and modes of delivery see Table 1.
The baseline AT level (at 6 wks postpartum) was 109 IU/dL (95%
CI 93, 124) and was the same as the mean third trimester level
(109 IU/dL [95% CI 97, 120]). The mean level on admission for child-
birth was lower (93 IU/dL [95% CI 80, 107]). Immediately after child-
birth, levels dropped precipitously and were signiﬁcantly below
baseline by 4 hours postpartum (88 IU/dL [95% CI 77, 99]) (p b 0.05)
and reached a nadir at 12 hours postpartum (76 IU/dL [95% CI 53, 99])
(p b 0.05). The nadir was more than 30% below baseline. AT levels
remained signiﬁcantly below baseline at 24 hours postpartum (88 IU/dL
[95% CI 67, 108]) (p b 0.05) before rising and returning to baseline by
72 hours postpartum (111 IU/dL [95% CI 92, 129]). Fig. 3 illustrates the
nadir in relation to levels during pregnancy aswell as the timing of recov-
ery of AT levels after childbirth. AT levels, which returned to baseline at
72 hours, continued to rise slightly until 2 weeks PP (117 IU/dL [95% CI
104, 129], then declined to baseline and plateaued for the remainder of
the postpartum period.
Discussion
We found that, overall, AT levels were 20% lower than baseline dur-
ing pregnancy. Additionally from the second analysis (cohort) weFig. 2. Serial antithrombin levels from a single cohort (n = 120) sampled in the late ﬁrst
trimester, in the late second trimester and at 6 weeks postpartum (PP).learned that there was no difference between AT levels obtained
between 12 to 14 weeks gestation (the end of the ﬁrst trimester) and
24 to 28 weeks gestation (the end of the second trimester). Whether
we would have found a difference between levels obtained at the end
of the second trimester and levels obtained in the third trimester had
we sampled then is unknown, but there was a remarkable difference
between AT levels obtained during pregnancy and AT levels obtained
at baseline (6 weeks postpartum). From the ﬁrst analysis (corss-sec-
tional) we learned that from midtrimester to term (25 to 40 weeks
gestation), AT levels were negatively correlated with gestational age
with a 13% drop during this period of time. From the third analysis (co-
hort), where frequent serial sampling was performed, we learned that
immediately after childbirth, AT levels fell precipitously to 30% below
baseline and reached a nadir 12 hours postpartum before rising and
returning to baseline by 72 hours postpartum. This precipitous fall im-
mediately after childbirth is a novel ﬁnding and has not been previously
reported.
Previous investigators have found decreased AT levels in the third
trimester of pregnancy or immediately postpartum and others have
found no change [16–22]. This variation in results is likely because the
decreases in AT levels are not large until the immediate postpartum
period and then the dramatic decreases are ﬂeeting. Depending on
how the studieswere conducted and howmany subjects were sampled,
the pattern of the changes in AT levels could have been missed. With
subjects from three different secondary analyses and using frequent, se-
rial sampling in the immediate postpartum period, wewere able to elu-
cidate the pattern of the changes.
The more dramatic changes observed in the immediate postpartum
period may be easier to explain than the smaller changes observed dur-
ing pregnancy. It is possible that the changes observed during pregnan-
cy can be explained by hemodilution, altered synthesis, increased
clearance or even a consumptive process. These were normal subjects
who did not have renal disease or preeclampsia and would not have
been expected to have lost antithrombin through urinary excretion.
The precipitous drop in AT levels in the immediate postpartum period
suggests a consumptive process consistent with thrombus formation.
A recent study demonstrated that more than half of women have MRI
evidence of non-occlusive thrombi in their pelvic veins 1–4 days after
vaginal delivery [24]. The same investigators found a similarly high
rate of non-occlusive thrombi at the time of discharge after cesarean
delivery [25]. We have previously reported other biochemical evidence
of this thrombotic processwith consumption of ﬁbrinogen [26] and fac-
tor VIII [27] at the time of delivery. It should be noted that while there
were signiﬁcant changes in AT levels during pregnancy and the postpar-
tum period, most values remained in the normal range for the assay.
Limitations of this study are the lack of frequent, serial samples
antepartum. In none of the studies were frequent, serial samples taken
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levels. Data from the second analysis (cohort) might have conﬁrmed
the ﬁnding from the ﬁrst analysis (cross-sectional) of a 13% decrease
in AT levels in the third trimester, but in the second analysis (cohort),
frequent, serial samples were not obtained in the third trimester. None-
theless, frequent, serial samples were taken in the third analysis (co-
hort) during the postpartum period leading to the discovery of the
novel ﬁnding of the precipitous drop in AT levels during the immediate
postpartum period. Unfortunately, there were insufﬁcient subjects to
elucidate whether there were differences in the pattern of AT levels
between women who had a spontaneous vaginal delivery, a cesarean
delivery before labor or a cesarean delivery after labor, nor did the
study provide data on the pattern of AT levels in women with pre-
eclampsia or AT deﬁciency. The response of AT levels in these other con-
ditions and situations could have implications for AT replacement
during different clinical scenarios.
In conclusion,we found that AT levels are 20% below baseline during
pregnancy. It appears that this decrease is present by the end of the ﬁrst
trimester. There is a further decline of approximately 13% after
midtrimester. Then, it appears that antithrombin is consumed at the
time of delivery consistent with temporary thrombus formation. The
mean antithrombin level drops 30% after delivery with a nadir at
12 hours postpartum before returning to baseline at 72 hours postpar-
tum. These ﬁndings may have implications for the management of AT
replacement in patients with either AT deﬁciency or an AT-deﬁcient
disease state such as severe preeclampsia and may have implications
for anticoagulation for all patients at risk for pregnancy-related
thrombosis.
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